Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.34B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.68M
Average 0.58M
KYMR Pre-Tax Margin
Income before tax as a percentage of revenue.
Kymera Therapeutics, Inc.NASDAQ: KYMR
Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026
Pre-tax margin widens to -94.2%
Pre-tax margin was -94.2% in Q2 FY2026, up 573.4 pp from a year earlier. On a trailing-twelve-month basis it was -285.6%, up 330.4 pp year over year. Over 3 fiscal years it narrowed by 464.4 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -795.0%
- Year-over-year change
- -319.4pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -795.0% | -319.4pp |
| FY2024 | 2024-12-31 | -475.6% | -288.6pp |
| FY2023 | 2023-12-31 | -187.0% | +143.6pp |
| FY2022 | 2022-12-31 | -330.6% | -193.0pp |
| FY2021 | 2021-12-31 | -137.6% | — |
Pre-Tax Margin vs competitors
How KYMR compares with its peers on the latest reported figures
- KYMR's LTM Jun 2026 pre-tax margin of -285.6% is the 3rd highest of the 5 companies compared; the peer median is -272.3%.
- Its year-over-year change of +330.4 pp is the 2nd highest of 5, against a peer median of -137.3 pp.
- Over three fiscal years its change of -464.4 pp compares with a peer median of +152.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 43.9% | +335.5 pp | +152.9 pp | |
| LTM Mar 2026 | -247.2% | -236.4 pp | +168.4 pp | |
| LTM Jun 2026 | -285.6% | +330.4 pp | -464.4 pp | |
| LTM Mar 2026 | -297.4% | -38.1 pp | +120.4 pp | |
| LTM Mar 2026 | -307.0% | -313.0 pp | — | |
| Peer median (excluding KYMR) | -272.3% | -137.3 pp | +152.9 pp | |
Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M |
| Selling, General & Admin | 36.35M | 43.83M | 55.04M | 63.53M | 68.2M |
| Operating Expenses | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M |
| Depreciation & Amortization | 2.4M | 2.98M | 3.57M | 7.37M | 8.31M |
| EBITDA | (97.65M) | (151.66M) | (143.2M) | (216.24M) | (303.06M) |
| EBITDA Margin | -134.1% | -323.9% | -182.2% | -459.4% | -773.1% |
| Operating Income | (100.53M) | (161.26M) | (165.53M) | (261.64M) | (349.4M) |
| Operating Margin | -138.0% | -344.4% | -210.6% | -555.8% | -891.3% |
| Interest Income | 488K | 6.62M | 18.76M | 38.03M | 38.03M |
| Interest Expense | 175K | 176K | 196K | 249K | 249K |
| Other Income / Expenses | 313K | 6.45M | 18.57M | 37.78M | 37.78M |
| Income Before Tax | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.62M) |
| Pre-Tax Margin | -137.6% | -330.6% | -187.0% | -475.6% | -795.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.22M) | (154.81M) | (146.96M) | (223.86M) | (311.4M) |
| Net Margin | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (Basic) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| EPS (Diluted) | (2.09) | (2.87) | (2.52) | (2.98) | (3.69) |
| Weighted Avg Shares | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
| Weighted Avg Shares (Diluted) | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M |
Kymera Therapeutics, Inc.
NASDAQ:KYMR
Intrinsic Alpha fair value
Locked
Current Price
$121.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.